Stereotaxis (STXS) announced it obtained CE Mark in Europe and submitted a 510(k) application to the FDA in the US for the Synchrony system. “Synchrony and SynX are central to our digital surgery efforts to modernize the interventional lab with enhanced workflow, remote connectivity, and smart AI capabilities,” said David Fischel, Stereotaxis Chairman and CEO. “The technology improves the robotic cockpit, and will be critical in supporting future robotic efforts for remote long-distance procedures and automated catheter navigation. The opportunity is much broader than robotic labs as we believe all cath labs stand to benefit from improved workflow, connectivity, and collaboration.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on STXS:
- Here’s Why Astria Therapeutics Stock (ATXS) Exploded Today
- Strategic Collaboration and Market Expansion Drive Buy Rating for Stereotaxis
- Stereotaxis, CardioFocus collaborate to advance robotic PFA technology
- Stereotaxis announces procedures using Genesis at Erasmus Medical Center
- Stereotaxis announces completion of procedure using MAGiC Sweep